
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (ANRO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
anro · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Alto Neuroscience, Inc. (ANRO) measures how much investors pay for each dollar of the company's trailing earnings. ANRO's current PE ratio of N/A is calculated by dividing its stock price of $18.21 by its TTM earnings per share of -$2.26.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Alto Neuroscience, Inc.You ANRO | $639M | N/A | — | -$2.26 |
AC Immune S.A. ACIU | $225M | N/A | — | -$0.70 |
Aldeyra Therapeutics, Inc. ALDX | $107M | N/A | — | -$0.56 |
Amarin Corporation plc AMRN | $293M | N/A | — | -$1.87 |
Cellectis S.A. CLLS | $297M | N/A | — | -$0.67 |
Contineum Therapeutics, Inc. Class A Common Stock CTNM | $419M | N/A | — | -$2.17 |
DBV Technologies S.A. DBVT | $391M | N/A | — | -$1.70 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.19 | — | |
2024-12-31 FY2024 | — | $-2.50 | — | |
2023-12-31 FY2023 | — | $-1.35 | — | |
2022-12-31 FY2022 | — | $-1.08 | — | |
2021-12-31 FY2021 | — | $-0.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Alto Neuroscience, Inc. (ANRO) measures how much investors pay for each dollar of the company's trailing earnings. ANRO's current PE ratio of N/A is calculated by dividing its stock price of $18.21 by its TTM earnings per share of -$2.26.
Frequently asked questions
ANRO pe ratio · 6 questionsANRO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $18.21 and TTM EPS of -$2.26. Data sourced from Financial Modeling Prep via ANRO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alto Neuroscience, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08